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LETTER TO THE EDITOR
Do phenothiazines contribute to tumour regressions in lymphokine-
activated killer cell/interleukin-2 treatments of renal cell cancer?
Sir - Phenothiazines are known to exhibit antitumour
activity (Belkin & Hardy, 1957). They are used routinely for
the prevention of treatment-induced nausea in cancer
patients not only during treatment with cytotoxic drugs but
also during administration of lymphokine - activated killer
(LAK) cells and interleukin-2 (IL-2). With the LAK cell/IL-2
treatment tumour regressions are mainly observed in renal
cell cancer patients and melanoma patients (Rosenberg et al.,
1985). The present experiments were performed to examine a
possible cytostatic activity of phenothiazines on human renal
cancer cells. Four commercially available phenothiazines
were tested (Table I) on human renal cancer cells as recently
described (Sauter & Cogoli, 1987).
Growth inhibition was observed with all of the four
phenothiazines examined at concentrations similar to that of
nitrogen mustard (Table I). The maximal effect was reached
between 20 and 40h of drug:cell contact. Drug-cell contact
as short as seven minutes already produced a definite growth
inhibition (Figure 1).
The phenothiazine concentrations necessary to cause
growth inhibition of renal cancer cells in vitro are around
20pM whereas plasma levels of chlorpromazine rarely exceed
0.6/M (Simpson et al., 1980). Despite this 30-fold difference
in concentrations an in vivo antitumour activity of
phenothiazines is quite possible due to selective high
concentrations in certain tumour tissues (Fairchild et al.,
1982): Interestingly enough LAK cell/IL-2 treatments induce
tumour regressions in melanomas (Rosenberg et al., 1985)
where chlorpromazine is known to accumulate (Fairchild et
al., 1982). If in renal cell cancers the same selective
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Table I Growth inhibition (GI) of hypernephroma cells by four
phenothiazines and nitrogen mustard (continuous exposure)
Minimal concentration (#M) for:
Drug complete GI detectable GI
chlorpromazine 30 15
(LargactilR)
prochlorperazine 27 13
(CompazineR; StemetilR)
promazine 88 35
(PrazineR)
promethazine 88 35
(PhenerganR)
nitrogen mustard 32 0.3
(MustargenR)
concentration occurs phenothiazines might well contribute to
tumour regressions in LAK cell/IL-2 treatments.
Yours etc.,
C. Sauter
Division ofOncology,
Department of Medicine,
University Hospital,
CH-8091 Zurich, Switzerland.
This work was supported by the 'Schweizerische Krebsliga'. I thank
Mrs Ch. Meier and Miss L. Resenterra for technical assistance and
Mrs E. Sauter for linguistic help.
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Figure 1 Example of growth inhibition of hypernephroma cells by chlorpromazine: (a) Continuous drug contact (4 days). 1:
Medium control (complete monolayer) 2-6: Decreasing concentrations of chlorpromazine (uM): 30; 15; 3; 1.5; 0.3. 2: Complete
growth inhibition 3: Detectable growth inhibition 4-6: No growth inhibition (b) Time of drug contact 7min. 1: Medium control
(complete monolayer) 2-6: Decreasing concentrations of chlorpromazine (pM): 313; 156; 30; 15; 3. 2 and 3: complete growth
inhibition 4-6: no growth inhibition
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